# Satellos Bioscience (MSLE) — News

MSLE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/msle/news

## Recent headlines

- [Satellos granted composition of matter patent for Forazapadin](https://www.ainvest.com/news/satellos-granted-composition-matter-patent-forazapadin-2610) — AInvest Wire, Oct 5, 2026
- [Satellos Bioscience - FSHD Canada Foundation to provide up to $5 mln non-dilutive financing for Forazapadin in FSHD](https://www.ainvest.com/news/satellos-bioscience-fshd-canada-foundation-provide-5-mln-dilutive-financing-forazapadin-fshd-2609) — AInvest Wire, Sep 24, 2026
- [Satellos Bioscience - Phase 2 study of forazapadin in FSHD expected to begin in Q4 2026](https://www.ainvest.com/news/satellos-bioscience-phase-2-study-forazapadin-fshd-expected-q4-2026-2609) — AInvest Wire, Sep 24, 2026
- [Satellis Bioscience Inc: H.C. Wainwright raises target price to $18 from $11](https://www.ainvest.com/news/satellis-bioscience-wainwright-raises-target-price-18-11-2607) — AInvest Wire, Jul 9, 2026
  Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) has seen recent analyst activity with H.C. Wainwright & Co. raising its price target for the stock to $18 from $11, maintaining a "Buy" rating. This adjustment reflects growing confidence in the company's clinical progress and regulatory momentum.…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).